
|Articles|January 15, 2003
Improved form of brimonidine has fewer contraindications
Brimonidine tartrate 0.15% (Alphagan P, Allergan) is a "new and improved" version of brimonidine 0.2% (Alphagan, Allergan). It continues to have an efficacy profile similar to the one ophthalmologists have grown used to with brimonidine 0.2%.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
2
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
3
Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists
4
Optigo Biotherapeutics names Andreas Wallnöfer, PhD, MBA, to board as lead retinal program advances
5


















































.png)


